Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer

Clin Lung Cancer. 2017 Jan;18(1):e81-e83. doi: 10.1016/j.cllc.2016.10.001. Epub 2016 Oct 26.

¹ Department of Medicine, Weill Cornell Medical College, New York, NY.
² Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
³ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
⁴ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
⁵ Department of Medicine, Weill Cornell Medical College, New York, NY; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
⁶ Department of Medicine, Weill Cornell Medical College, New York, NY; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: yuh@mskcc.org.

No abstract available

Keywords: Drug toxicity; Drug-induced pneumonitis; EGFR-mutant lung cancer; EGFR-tyrosine kinase inhibitors; Interstitial lung disease.

Publication types